Is Mitotane a chemotherapy drug or a targeted therapy drug?

Mitotane is a special type of drug mainly used to treat adrenocortical carcinoma (Adrenocortical carcinoma, ACC). It is neither a chemotherapy drug in the traditional sense nor a typical targeted therapy drug. Mitotane has a unique mechanism of action and is more classified as an anti-adrenocortical steroid drug. It has a cytotoxic effect and can selectively destroy adrenocortical cells, thereby inhibiting tumor growth and hormone secretion.

Mitotane is not a common chemotherapy drug. Traditional chemotherapy drugs usually kill rapidly proliferating cancer cells by interfering with the cell division process, while mitotane mainly targets the mitochondrial function of adrenocortical cells and destroys their metabolic processes. It causes cancer cell death by changing the stability of the adrenal cell membrane and affecting the energy metabolism of mitochondria. Because it targets a metabolic pathway unique to the adrenal cortex, it shows specificity in the treatment of adrenocortical cancer.

Mitotan does not belong to the category of modern targeted therapy drugs. Targeted therapy usually targets receptors on the surface of cancer cells or intracellular signaling pathways for precise attacks, while mitotane's mechanism of action is more extensive and does not target specific gene mutations or signaling pathways. Nonetheless, due to its specific metabolic pathway for adrenocortical cancer, mitotane can be considered to some extent a functional "targeted" drug, but strictly speaking, it still belongs to a special class of drugs other than chemotherapy drugs.

The clinical application of mitotane mainly focuses on the adjuvant treatment of adrenocortical cancer and the control of advanced adrenal cancer. Because this type of cancer is rare and difficult to treat, mitotane provides a more effective drug option. The use of mitotane requires strict monitoring of drug concentration and side effects, and the treatment process is often combined with surgery and other adjuvant therapies. In general, mitotane is a cytotoxic drug specifically targeting adrenocortical cancer, which is different from traditional chemotherapy drugs and atypical targeted therapy drugs.

Reference materials:https://go.drugbank.com/drugs/DB00648